The US Food and Drug Administration approved daraxonrasib, sold as Rasonque, on August 26 for adults with metastatic pancreatic adenocarcinoma, creating the first approved treatment aimed broadly at the RAS proteins that drive most cases of the disease. The once-daily tablet is authorized for patients who have received at least one previous systemic therapy or cannot receive a multi-drug systemic regimen.
The decision rests on RASolute 302, a randomized, open-label trial of 500 adults whose metastatic cancer had progressed after prior treatment. FDA data show median overall survival of 13.2 months with daraxonrasib, compared with 6.7 months for physician-selected standard chemotherapy. Median progression-free survival was 7.2 months versus 3.6 months, while tumors responded in 30% of patients on the drug and 11% on chemotherapy.
Daraxonrasib acts as a molecular glue, working with the protein cyclophilin A to block active RAS signaling. Dana-Farber Cancer Institute said more than 90% of pancreatic cancers carry cancer-driving mutations in KRAS, part of the RAS family. Researchers had long viewed these proteins as exceptionally difficult drug targets, making the approval a major change in a field with few effective options.
The result does not mean the medicine is a cure. Associated Press cited cancer specialists describing it as a significant improvement for a disease often detected only after it has spread. The American Cancer Society estimates about 67,000 US diagnoses and more than 52,000 deaths this year, while overall five-year survival remains about 13%. The company set an approximate monthly list price of $39,800 before insurance or discounts.
Treatment still carries substantial risks. FDA warnings cover skin and soft-tissue toxicity, mouth inflammation, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and harm to a fetus. Specialist reporting found severe adverse events in 62% of daraxonrasib recipients and 70% of chemotherapy recipients; one patient died from treatment-related pneumonitis. Rash, diarrhea and stomatitis were especially common.
The FDA approved the medicine about six and a half months before its target date after granting priority review, breakthrough-therapy and orphan-drug designations. Health Canada collaborated through Project Orbis, while European and Japanese regulators observed the review and may still be assessing applications. Researchers are also testing the RAS-targeting approach in other cancers, but access, cost, long-term safety and performance beyond the trial population will shape its real-world impact.
Comments